Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: Can survival rates of randomized controlled trials be achieved?
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Real-world glioblastoma survival data from a German center were compared to randomized controlled trial (RCT) data. Patients not meeting RCT criteria had significantly poorer outcomes, highlighting disparities in clinical trial representation.
Area Of Science
- Neuro-oncology
- Clinical Trial Analysis
- Real-World Evidence
Background
- Glioblastoma patient survival data vary significantly across studies.
- This study investigates the applicability of existing data in a German real-world population.
- Comparison of real-world data against randomized controlled trial (RCT) survival data is crucial.
Purpose Of The Study
- To assess the relevance of glioblastoma survival data in a real-world German cohort.
- To compare real-world patient outcomes with data from randomized controlled trials (RCTs).
- To identify factors influencing survival discrepancies between real-world data and RCTs.
Main Methods
- Analysis of newly diagnosed glioblastoma patient data from a single German center (2010-2019).
- Matching treatment patterns and survival rates to existing real-world data and RCT results.
- Comparison of outcomes between patients meeting and not meeting RCT eligibility criteria.
Main Results
- Overall survival (OS) was significantly impacted by age, extent of resection, MGMT methylation status, and ECOG performance status.
- The median OS for the entire study population was 10.55 months.
- Patients not meeting RCT eligibility criteria had a significantly lower median OS (6.9 months) compared to a simulated RCT cohort (14.3 months).
Conclusions
- Real-world glioblastoma patient survival, particularly for those with unfavorable prognostic factors, remains poor.
- RCT outcome data can be transferable to real-world cohorts only if eligibility criteria are met.
- A significant survival disadvantage exists for patients excluded from RCTs, underscoring the need for broader trial representation.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
